Skip to main content

Abstract

The occurrence of intestinal diseases such as colon cancer is closely related to the intestinal flora. Lactobacillus fermentum is a gut probiotic that plays an important role in chronic intestinal inflammation and colon cancer. In the current study, we investigated the effect of Lactobacillus fermentum ZS40 on NF-κB signaling pathway of azomethane-dextran sulfate sodium (AOM-DSS) -induced colon cancer in mice. Animals were divided into control group (NC), AOM-DSS-induced model group (CRC), AOM-DSS plus high-dose Lactobacillus fermentum ZS40 (ZS40-H), AOM-DSS plus low-dose Lactobacillus fermentum ZS40 (ZS40-L), AOM-DSS plus Lactobacillus bulgaricus (BLA), and AOM-DSS plus sulfasalazine (SD)-treated group. Observation of animal physiological activity (body weight and defecation), biochemical measurements, histopathological examination of colon tissue, qPCR to evaluate the expression of inflammation-related genes, immunohistochemical analysis of CD34 and CD117, and Western blot analysis of NF-κB signaling pathway were performed. Compared with the CRC group, the ZS40-H, ZS40-L, BLA, and SD groups had decreased levels of colon cancer marker proteins CD34 and CD117, and the number of abnormal colonic lesions observed by colon histology decreased, while the ZS40-H group showed excellent results. In addition, all probiotic interventions showed weight loss effects. The expression of inflammatory stimulators TNF-α and IL-1β in the probiotic treatment group decreased; the expression of key proteins IκBα and p65 in the NF-κB signaling pathway also decreased, resulting in a decrease in the expression of the target protein Cox-2. Therefore, administration of Lactobacillus fermentum ZS40 as a probiotic can alleviate intestinal inflammation and prevent colon cancer in mice.

Keywords: AOM-DSS; Lactobacillus fermentum; NF-κB signaling pathway; colon cancer; inflammation-related genes.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus fermentumReduced Body WeightBeneficial
Moderate
Lactobacillus fermentumReduced Incidence of Colon CancerBeneficial
Large
Lactobacillus fermentumReduced Inflammation LevelsBeneficial
Large
Lactobacillus fermentum Lf-33Reduced Abnormal Colonic LesionsBeneficial
Large
Lactobacillus fermentum Lf-33Reduced Activation of TLR4/NF-κB Signaling PathwayBeneficial
Moderate
Lactobacillus fermentum Lf-33Reduced Body WeightBeneficial
Moderate
Lactobacillus fermentum Lf-33Reduced Colon Cancer Marker ProteinsBeneficial
Large
Lactobacillus fermentum Lf-33Reduced Inflammatory StimulatorsBeneficial
Large
Lactobacillus fermentum LF61Inhibited NF-kB Pathway ActivationBeneficial
Large
Lactobacillus fermentum LF61Reduced Abnormal Colonic LesionsBeneficial
Large
Lactobacillus fermentum LF61Reduced Body WeightBeneficial
Moderate
Lactobacillus fermentum LF61Reduced Colon Cancer Marker ProteinsBeneficial
Large
Lactobacillus fermentum LF61Reduced Inflammatory StimulatorsBeneficial
Large

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.